Department of Immunopathology, Sanquin Research, Amsterdam, Netherlands.
Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Front Immunol. 2019 Feb 22;10:181. doi: 10.3389/fimmu.2019.00181. eCollection 2019.
Clinical studies with cellular therapies using tolerance-inducing cells, such as tolerogenic antigen-presenting cells (tolAPC) and regulatory T cells (Treg) for the prevention of transplant rejection and the treatment of autoimmune diseases have been expanding the last decade. In this perspective, we will summarize the current perspectives of the clinical application of both tolAPC and Treg, and will address future directions and the importance of immunomonitoring in clinical studies that will result in progress in the field.
过去十年，使用诱导耐受细胞的细胞疗法（如耐受原性抗原呈递细胞和调节性 T 细胞）在预防移植排斥和治疗自身免疫性疾病方面的临床研究一直在不断扩展。在此背景下，我们将总结目前关于 tolAPC 和 Treg 的临床应用的观点，并探讨未来的方向以及免疫监测在临床研究中的重要性，这将推动该领域的进展。
